文字サイズ
TBGUポータルサイト

東北文化学園大学 Tohoku Bunka Gakuen University

TOP > 抗感染症薬開発研究部門 > 研究業績

研究業績

2013年1月から2025年5月までの主な業績を以下に記します。

英文（原著論文）

1Kohno S, Imamura Y, Shindo Y, Seki M, Ishida T, Teramoto S, Kadota J, Tomono K and Watanabe A: Clinical practice guidelines for nursing- and healthcare-associated pneumonia (NHCAP)[Complete translation]. Respiratory Investigation 51(2):103-126, 2013.
2Fuse K, Fujimura S, Kikuchi T, Gomi K, Iida Y, Nukiwa T and Watanabe A: Reduction of virulence factor pyocyanin production in multidrug-resistant Pseudomonas aeruginosa. J Infect Chemother 19(1):82-88,2013.
3Watanabe A: A randomized double-blind controlled study of laninamivir comparing with oseltamivir for the treatment of influenza in patients with chronic respiratory diseases. J Infect Chemother 19(1):89-97,2013.
4Hayami H, Takahashi S, Ishikawa K, Yasuda M, Yamamoto S, Uehara S, Hamasuna R, Matsumoto T, Minamitani S, Watanabe A, Iwamoto A, Totsuka K, Kadota J, Sunakawa K, Sato J, Hanaki H, Tsukamoto T, Kiyota H, Egawa S, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Kobayashi K, Matsubara A, Naito S, Tatsugami K, Yamaguchi T, Ito S, Kanokogi M, Narita H, Kawano H, Hosobe T, Takayama K, Sumii T, Fujii A, Sato T, Yamauchi T, Izumitani M, Chokyu H, Hara H, Akiyama K, Yoshida M, Uno S, Monden K, Kano M, Kaji S, Kawai S, Ito K, Inatomi H, Nishimura H, Ikuyama T, Nishi S, Takahashi K, Kwano Y, Ishihara S, Tsuneyoshi K, Matsushita S, Yamane T, Hirose T, Fujihiro S, Endo K, Oka Y, Takeyama K, Kimura T and Uemura T: Nationwide surveillance of bacterial pathogens from patients with acute uncomplicated cystitis conducted by the Japanese surveillance committee during 2009 and 2010: antimicrobial susceptibility of Escherichia coli and Staphylococcus saprophyticus. J Infect Chemother 19(3):393-403, 2013.
5Fujita J, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Tanigawara Y, Cash HL and Kohno S: Clinical and bacteriological efficacies of sitafloxacin against community-acquired pneumonia caused by Streptococcus pneumoniae: nested cohort within a multicenter clinical trial. J Infect Chemotherpy 19(3):472-479, 2013.
6Kohno S, Niki Y, Kadota J, Yanagihara K, Kaku M, Watanabe A, Aoki N, Hori S, Fujita J, and Tanigawara Y: Clinical dose findings of sitafloxacin treatment: Pharmacokinetic- pharmacodynamic analysis of two clinical trial results for community-acquired respiratory tract infections. J Infect Chemother 19(3):486-494, 2013.
7Hamasuna R, Yasuda M, Ishikawa K, Uehara S, Takahashi S, Hayami H, Yamamoto S, Matsumoto T, Minamitani S, Watanabe A, Iwamoto A, Totsuka K, Kadota J, Sunakawa K, Sato J, Hanaki H, Tsukamoto T, Kiyota H, Egawa S, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Kobayashi K, Matsubara A, Naito S, Tatsugami K, Ito S, Narita H, Kanokogi M, Sumii T, Ito K, Hosobe T, Kawai S, Kawano H, Takayama K, Yamaguchi T, Endo K, Yamauchi T, Maeda S, Yoh M, Horie M, Ito M, Chokyu H, Ihara H, Akiyama K, Uno S, Monden K, Kaji S, Nishimura H, Kawahara M, Sato T, Koniishi T, Nishi S, Ishihara S and Yoshioka M: Nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan. J Infect Chemother 19(4):571-578,2013.
8Kashiwagi S, Watanabe A, Ikematsu H, Awamura S, Okamoto T, Uemori M and Ishida K: Laninamivir octanoate for post-exposure prophylaxis of influenza in household contacts: a randomized double blind placebo controlled trial. J Infect Chemother 19(4):740-749,2013.
9Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka N, Eguchi K, Watanabe A, Origasa H, Iwai K, Sakamaki Y, D van der Heijde, Miyasaka N and Koike T. Efficacy and safety of certolizumab pegol without methotrexate co-administration in Japanese patients with active rheumatoid arthritis: The HIKARI randomised, placebo-controlled trial. Mod Rheumatol 24(4):552-560,2014.
10Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka N, Eguchi K, Watanabe A, Origasa H, Shoji T, Sakamaki Y, van der Heijde D, Miyasaka N and Koike T. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol 24(5):715-724. 2014.
11Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N and Koike T: Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients who could not receive methotrexate: 52-week results from an open-label extension of the HIKARI study. Mod Rheumatol 24(5):725-733. 2014.
12Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N and Koike T: Long-term efficacy and safety of certolizumab pegol in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: 52-week results from an open-label extension of the J-RAPID study. Mod Rheumatol 24(5):734-743. 2014.
13Kikuchi T, Kobashi Y, Hirano T, Tode N, Santoso A, Tamada T, Fujimura S, Mitsuhashi Y, Honda Y, Nukiwa T, Kaku M, Watanabe A and Ichinose M. Mycobacterium avium genotype is associated with the therapeutic response to lung infection. Clinical Microbiology and Infection 20(3):256-262, 2014.
14Kohno S, Tateda K, Kadota J, Fujita J, Niki Y, Watanabe A and Nagashima M: Contradiction between in vitro and clinical outcome: Intravenous followed by oral azithromycin therapy demonstrated clinical efficacy in macrolide-resistant pneumococcal pneumonia. J Infect Chemothr 20(3):199-207, 2014.
15Naito T, Matsuda N, Tanei M, Watanabe Y and Watanabe A: Relationship between public subsidies and vaccination rates with the 23-valent pneumococcal vaccine in elderly persons, including the influence of the free vaccination campaign after the great East Japan earthquake. J Infect Chemothr 20(7):450-453, 2014.
16Izumikawa K, Watanabe A, Miyashita N, Ishida T and Kohno S: Efficacy and safety of garenoxacin tablets on clinically diagnosed atypical pneumonia: postmarketing surveillance in Japan. J Infect Chemother 20(9):541-548. 2014.
17Izumikawa K, Watanabe A, Miyashita N, Ishida T and Kohno S: Efficacy and safety of garenoxacin tablets on bacterial pneumonia: postmarketing surveillance in Japan. J Infect Chemother 20(9):549-557, 2014.
18Fujimura S, Nakano Y, Watanabe A: A correlation between reduced susceptibilities to vancomycin and daptomycin among the MRSA isolates selected in mutant selection window of both vancomycin and daptomycin. J Infect Chemother 20(12):752-756, 2014.
19Yamamoto Y, Ohmichi M, Watanabe A, Niki Y, Aoki N, Kawai S, Chida K, Mikasa K, Seki M, Ishida T, Kadota J, Matsuse A, Fujita J and Kohno S. A study on the management of acute respiratory tract infection in adults. Jpn J Antibiotics 67(4):223-232, 2014.
20Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, and Koike T: Early response to certolizumab pegol predicts long-term outcomes in patients with active rheumatoid arthritis: results from the Japanese studies. Mod Rheumatol 25(1):11-20, 2015.
21Watanabe A, Yates PJ, Murayama M, Soutome T and Furukawa H: Evaluation of safety and efficacy of intravenous zanamivir in the treatment of hospitalized Japanese patients with influenza: an open-label, single arm study. Antiviral Ther 20(4):415-423, 2015.
22Hamasuna R, Yasuda M, Ishikawa K, Uehara S, Hayami H, Takahashi S, Matsumoto T, Yamamoto S, Minamitani S, Watanabe A, IwataS, Kaku M, Kadota J, Sunakawa K, Sato J, Hanaki H, Tsukamoto T, Kiyota H, Egawa S, Deguchi T, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Kobayashi K, Matsubara A, Naito S, Kuroiwa K, Hirayama H, Narita H, Hosobe T, Ito S, Ito K, Kawai S, Ito M, Chokyu H, Matsumura M, Yoshioka M, Uno S, Monden K, Takayama K, Kaji S, Kawahara M, Sumii T, Kadena K, Yamaguchi T, Maeda S, Nishi S, Nishimura H, Shirane T, Yoh M, Akiyama K, Imai T and Kano M: The second nationwide surveillance of the antimicrobial susceptibility of Neisseria gonorrhoeae from male urethritis in Japan, 2012-2013. J Infect Chemother 21(5):340-345, 2015.
23Yanagihara K, Kadota J, Aoki N, Matsumoto T, Sato J, Ogasawara K, Wakamura T, Sunakawa K, Watanabe A, Iwata S, Kaku M, Hanaki H, Ohsaki Y, Watari T, Takeuchi K, Shiokoshi M, Takeda H, Miki M, Nakanowatari S, Takahashi H, Utagawa M, Nishiya H, Kawakami S, Kobayashi N, Takasaki J, Mwzaki K, Konosaki H, Aoki Y, Yamamoto Y, Shoji M, Goto H, Saraya T, Kurai D, Okazaki M, Niki Y, Yoshida K, Kawana A, Saionji K, Miyazawa N, Kudo M, Sato Y, Yoshida T, Asano Y, Tsukada H, Imai Y, Honma Y, Tamamoto T, Ban N, Mikamo H, Sawamura H, Miyara T, Toda H, Sato K, Nakamura T, Fujikawa Y, Mitsuno N, Mikasa K, Sano R, Sugimoto K, Asari S, Nishi I, Miyashita N, Koguchi Y, Kusano N, Mihara E, Kuwabara M, Watanabe Y, Kawasaki Y, Takeda K, Tokuyasu H, Masui K, Negatyama K, Hiramatsu K, Aoki Y, Fukuoka M, Magaribuchi H, Nagasawa Z, Suga M, Muranaka H, Honda J, Fujita M: Nationwide surveillance of bacterial respiratory pathogens conducted by the Surveillance Committee of Japanese Society of Chemotherapy, Japanese Association for Infectious Diseases, and Japanese Society for Clinical Microbiology in 2010: general view of the pathogens' antibacterial susceptibility. J Infect Chemother 21(6):410-420, 2015.
24Tamayose M, Fujita J, Miyagi K, Maeshiro T, Hirata T, Higa F, Tateyama M, Watanabe A, Aoki N, Niki Y, Kadota J, Yanagihara K, Kaku M, Hori S and Kohno S: Correlations between extent of X-ray infiltration and levels of serum C-reactive protein in adult non-severe community-acquired pneumonia. J Infect Chemother 21(6):456-463, 2015.
25Suzuki K, Kurono Y, Ikeda K, Watanabe A, Iwamoto A, Totsuka K, Sunagawa K, Iwata S, Kadota J and Hanaki H: Nationwide surveillance of 6 otorhinolaryngological infectious diseases and antimicrobial susceptibility pattern in the isolated pathogens in Japan. J Infect Chemother 21(7):483-491, 2015.
26Ishikawa K, Hamasuna R, Uehara S, Yasuda M, Yamamoto S, Hayami H, Takahashi S, Matsumoto T, Minamitani S, Kadota J, Iwata S, Kaku M, Watanabe A, Sunakawa K, Sato J, Hanaki H, Tsukamoto T, Kiyota H, Egawa S, Deguchi T, Matsumoto M, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Kobayashi K, Matsubara A, Wakeda H, Amemoto Y, Onodera S, Goto H, Komeda H, Yamashita M, Takenaka T, Fujimoto Y, Tsugawa M,Takahashi Y, Maeda H, Onishi H, Ishitoya S, Nishimura K, Mitsumori K, Ito T, Togo Y, Nakamura I, Ito N, Kanamaru S, Hirose T, Muranaka T, Yamada D, Ishihara S, Oka H, Inatomi H, Matsui T, Kobuke M, Kunishima Y, Kimura T, Ichikawa T, Kagara I, Matsukawa M, Takahashi K, Mita K, Kato M, Okumura K, Kawanishi H, Hashimura T, Aoyama T, Shigeta M, Koda S, Taguchi K and Matsuda Y: Japanese nationwide surveillance in 2011 of antibacterial susceptibility patterns of clinical isolates from complicated urinary tract infection cases. J Infect Chemother 21(9):623-633, 2015.
27Fujimura S, Sato T, Hayakawa S, Kawamura M, Furukawa E and Watanabe A: Antimicrobial efficacy of combined clarithromycin plus daptomycin against biofilms-formed methicillin-resistant Staphylococcus aureus on titanium medical devices. J Infect Chemother 21(10):756-759,2015.
28Nakano Y, Fujimura S, Sato T, Kikuchi T, Ichinose M and Watanabe A: Sterilization method using plasma discharge against biofilm-producing Pseudomonas aeruginosa on surface of contact lens. Journal of Medical and Biological Engineering 35(5):626-633, 2015.
29Watanabe A, Matsumoto T, Igari H, Sawa J, Yamaguchi Y, Sakatani M: Risk of developing active tuberculosis in rheumatoid arthritis patients on adalimumab in Japan. Int J Tuber Lung Dis 20(1):101-108,2016.
30Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Okada T, Heijde D, Miyasaka N and Koike T: The first double-blind, randomised, parallel-group certolizumab pegol study in methotrexate-na?ve early rheumatoid arthritis patients with poor prognostic factors, C-OPERA, shows inhibition of radiographic progression. Ann Rhum Dis 75(1):75-83, 2016.
31Hirano T, Kikuchi T, Tode N, Santoso A, Yamada M, Mitsuhashi Y, Komatsu R, Kawabe T, Tanimoto T, Ishii N, Tanaka Y, Nishimura H, Nukiwa T, Watanabe A, Ichinose M: OX40 ligand newly expressed on bronchiolar progenitors mediates influenza infection and further exacerbates pneumonia. EMBO Mol Med. 8(4):422-436.2016.
32Takeuchi T, Yamamoto K, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, Watanabe A, Origasa H, Kobayashi M, Shoji T, Togo O, Miyasaka N, Koike T: Post-hoc analysis showing better clinical response with the loading dose of certolizumab pegol in Japanese patients with active rheumatoid arthritis. Mod Rheumatol 26(4):473-480, 2016.
33Kashiwagi S, Watanabe A, Ikematsu H, Uemori M, Awamura S: Long-acting neuraminidase inhibitor laninamivir octanoate as post-exposure prophylaxis for influenza. Clin Infect Dis 63(3):330-337,　2016.
34Takahashi S, Hamasuna R, Yasuda M, Ishikawa K, Hayami H, Uehara S, Yamamoto S, Minamitani S, Kadota J, Iwata S, Kaku M, Watanabe A, Sato J, Hanaki H, Masumori N, Kiyota H, Egawa S, Tanaka K, Arakawa S, Fujisawa M, Kumon H, Wada K, Kobayashi K, Matsubara A, Matsumoto T, Eto M, Tatsugami K, Kuroiwa K, Ito K, Hosobe T, Hirayama H, Narita H, Yamaguchi T, Ito S, Sumii T, Kawai S, Kanokogi M, Kawano H, Chokyu H, Uno S,Monden M, Kaji S, Kawahara M, Takayama K, Ito M, Yoshioka M, Kano M, Konishi T, Kadena H, Nishi S, Nishimura H, Yamauchi T, Maeda S, Horie M, Ihara H, Matsumura M, Shirane T, Takeyama K, Akiyama K, Takahashi K, Ikuyama T, Inatomi H, Yoh M: Nationwide surveillance of the antimicrobial susceptibility of Chlamydia trachomatis from male urethritis in Japan. J Infect Chemother 22(9):581-586, 2016. Availlable online July 21, 2016.
35Hayakawa S, Furukawa E, Kawamura M, Kikuchi T, Hirano T, Watanabe A, Fujimura S: Exposure to reactive oxygen species and piperacillin leads to multidrug resistance in Pseudomonas aeruginosa PAO1. Clin Microniol: Open access 5(6), p.1000264, published Nov.10, 2016.
36Atsumi T, Tanaka Y, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Yasuda S, Yamanishi Y, Kita Y, Matsubara T, Iwamoto M, Shoji T, Togo O, Okada T, Heijde D, Miyasaka N, and Koike T. Clinical benefit of 1-year certolizumab pegol (CZP) add-on therapy to methotrexate treatment in patients with early rheumatoid arthritis was observed following CZP discontinuation: 2-year results of the C-OPERA study, a phase III randomised trial. Ann Rheumat Dis 76(8):1348-1356, 2017.
37Tode N, Kikuchi T, Sakakibara T, Hirano T, Inoue A, Ohkouchi S, Tamada T, Okazaki T, Koarai A, Sugiura H, Niihori T, Aoki Y, Nakayama K, Matsumoto K, Matsubara Y, Yamamoto M, Watanabe A, Nukiwa T, Ichinose M. Exome sequencing deciphers a germline MET mutation in familial epidermal growth factor receptor-mutant lung cancer. Cancer Science 108(6):1263-1270, 2017.
38Tokuda H, Harigai M, Kameda ,H, Tomono K, Takayanagi N, Watanabe A, Tasaka S, Suda T, Tateda K, and Kadota J. Consensus statements for medical practice: Biological agents and Lung diseases [Abridged english translation by the Japanese Repiratory Spciety]. Respir Invest 55(3):229-251, 2017.
39Hirano T, Yamada M, Sato K, Murakami K, Tamai T, Mitsuhashi Y, Tamada T, Sugiura H, Sato N, Saito R, Tominaga J, Watanabe A, and Ichinose M. Invasive pulmonary mucormycosis: rare presentation with pulmonary eosinophilia. BMC Pulmonary Medicine 17:76, 2017.
40Takesue Y, Kusachi S, Mikamo H, Sato J, Watanabe A, Kiyota H, Iwata S, Kaku M, Hanaki　H, Sumiyama Y, Kitagawa Y, Mizuguchi T, Ambo Y, Konosu M, Ishibashi K, Matsuda A,Hase K, Harihara Y, Okabayashi K, Seki S, Hara T, Matsui K, Matsuo Y, Kobayashi M, Kubo S, Uchiyama K, Shimizu J, Kawabata R, Ohge H, Akagi S, Oka M, Wakatsuki T, Suzuki K, Okamoto K, Yanagihara K: Antimicrobial Susceptibility of pathogens isolated from surgical site infections in Japan: comparison of data from nationwide surveillance studies conducted in 2010 and 2014?2015. J Infect Chemother 23(6):339-348, 2017.
41Watanabe S, Ohnishi T, Yuasa A, Kiyota H, Iwata S, Kaku M, Watanabe A, Sato J, Hanaki H, Manabe M, Suzuki T, Otsuka F, Aihara M, Iozumi K, Tamaki T, Funada Y, Shinozaki M, Kobayashi M, Okuda M, Kikyo G, Kikuchi K, Okada Y, Takeshima M, Kaneko O, Ogawa N, Ito R, Okuyama R, Shimada S, Shimizu T, Hatta N, Maeda M, Tsutsui K, Tanaka T, Miyachi Y, Asada H, Furukawa F, Kurokawa I, Iwatsuki K, Hide M, Muto M, Yamamoto O, Niihara H, Takagaki K, Kubota Y, Sayama K, Sano S, Furue M, Kanekura T: The first nationwide surveillance of antibacterial susceptibility patterns of pathogens isolated from skin and soft-tissue infections in dermatology departments in Japan. J Infect Chemother 23(8):503-511, 2017.
42Yanagihara K, Watanabe A, Aoki N, Matsumoto T, Yoshida M, Sato J, Wakamura T, Sunakawa K, Kadota J, Kiyota H, Iwata S, Kaku M, Hanaki H, Ohsaki Y, Fujiuchi S, Takahashi M, Takeuchi K, Takeda H, Ikeda H, Miki M, Nakanowatari S, Takahashi H, Utagawa M, Nishiya H10), Kawakami S, Morino E, Takasaki J, Mezaki K, Chonabayashi N, Tanaka C, Sugiura H, Goto H, Saraya T, Kurai D, Iwata S, Katono Ya, Inose R, Niki Y, Yoshida K, Kudo M, Ehara S, Sato Y, Tsukada H, Watabe N, Aoki N, Honma Y, Mikamo H, Yamagishi Y, Nakamura A, Ohashi M, Seki M, Hamaguchi S, Toyokawa M, Fujikawa Y, Mitsuno N, Ukimura A, Miyara T, Nakamura T, Mikasa K, Kasahara K, Nakayama A, Fukuda S, Nakamura A, Morimura M, Yamashita M, Takesue Y, Wada Y, Sugimoto K, Kusano N, Nose M, Mihara E, Kuwabara M, Doi M, Watanabe Y, Tokuyasu H, Takeda K, Hino S, Negayama K, Mukae H,　Kawanami T, Ota T, Fujita M, Honda J, Hiramatsu K, Aoki Y, Fukuoka M, Magarifuchi H, Nagasawa Z, Kaku N, Fujita J, Higa F, Tateyama M.: Nationwide surveillance of bacterial respiratory pathogens conducted by the surveillance committee of Japanese Society of Chemotherapy, the Japanese Association for Infectious Diseases, and the Japanese Society for Clinical Microbiology in 2012: General view of the pathogens' antibacterial susceptibility. J Infect Chemother 23(9)587-597, 2017.
43Fujimura S, Sato T, Watanabe A: In silico evaluation of impurities found in some generic drugs of piperacillin/tazobactam. J Antimicrob Agents 3(2):1-3, 2017.
44Miyashita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchinou K, Ogasawara K, Kiyota H, and Watanabe A: Clinical presentation of Legionella pneumonia: evaluation of the clinical scoring systems and therapeutic efficacy. J Infect Chemother 23(11):727-732, 2017.
45Nakai H, Sato T, Uno T, Furukawa E, Kawamura M, Takahashi H, Watanabe A and Fujimura S: Mutant selection window of four quinolone antibiotics against clinical isolates of Streptococcus pneumoniae, Haemophilus influenzae and Moraxella catarrhalis. J Infect Chemother 24(2):83-87,2017.
46Miyashita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchinou K, Ogasawara K, Kiyota H, and Watanabe A: Diagnostic predictors of Legionella pneumonia in Japan. J Infect Chemother 24(3):159-163, 2018.
47Miyashita N, Kobayashi I, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchinou K, Ogasawara K, Kurachi S, Ishikawa T, Ishimura Y, Kanesaka I, Kiyota H, and Watanabe A: In vitro activity of various antibiotics against clinical isolates of Legionella species isolated in Japan. J Infect Chemother 24(5):325-329, 2018.
48Takesue Y, Kusachi S, Mikamo H, Sato J, Watanabe A, Kiyota H, Iwata S, Kaku M, Hanaki H, Sumiyama Y, Kitagawa Y, Nakajima K, Ueda T, Uchino M, Mizuguchi T, Ambo Y, Konosu M, Ishibashi K, Matsuda A, Hase K, Harihara Y, Okabayashi K, Seki S, Hara T, Matsui K, Matsuo Y, Kobayashi M, Kubo S, Uchiyama K, Shimizu J, Kawabata R, Ohge, Akagi S, Oka M, Wakatsuki T, Suzuki K, Okamoto K, Yanagihara K: Antimicrobial susceptibility of common pathogens isolated from postoperative intra-abdominal infections in Japan. J Infect Chemother 24(5):330-340, 2018.DOI: https://doi.org/10.1016/j.jiac.2018.02.011
49Hirano T, Ohkouchi S, Kobayashi M, Ono M, Satoh T, Mitsuishi Y, Watanabe A, Irokawa T, Ogawa H, Sugiura H, Kikuchi T, Akasaka K, Tazawa R, Inoue Y, Nakata K, Kurosawa H and Ichinose M: Alveolar nitric oxide concentration reflects macrophage inflammation and severities of auto-immune pulmonary alveolar proteinosis. ERJ open research 2018, 4:00071-2017[https://doi.org/10.1183/2312054.00071-2017].
50Naito T, Yokokawa H, Watanabe A: Impact of the national routine vaccination program on 23-valent pneumococcal polysaccharide vaccine vaccination rates in older persons in Japan. J Infect Chemother 24(6):496-498, 2018.
51Hayden FG, Sugaya N, Hirotsu N, Lee N, de Jong MD, Hurt AC, Ishida T, Sekino H, Yamada K, Pourtsmouse S, Kawaguchi K, Shishido T, Arai M, Tsuchiya K, Uehara T, Watanabe A: Baloxavir Marboxil for uncomplicated influenza in adults and adolescents. New Engl J Med 379(10):913-923, 2018(DOI: 10.1056/NEJMoa1716197)
52Hayakawa S, Kawamura M, Sato T, Kikuchi T, Hirano T, Kikuchi T, Watanabe A, and Fujimura S. An α-Lipoic acid derivative, and anti-ROS agent, prevents the acquisition of multi-drug resistance in clinical isolates of Pseudomonas aeruginosa. J Infect Chemother 25:28-33,2019. online: https://doi.org/10.1016/j.jiac.2018.10.003.
53Kikuchi T and Watanabe A: Editorial； Baloxavir opens a new era for influenza virus biology. Respiratory Investigation 57:1-2,2019. Online available 3 November 2018.
54Watanabe A, Ishida T, Hirotsu N, Kawaguchi K, Ishibashi T, Shishido T, Sato C, Portsmouth S, Tsuchiya K, and Uehara T. Baloxavie marboxil in Japanese patients with Seasonal influenza: Dose response and virus type/subtype outcomes from randomized phase 2 study. Antiviral Research 163:75-81, 2019. https://doi.org/10.1016/j.antiviral.2019.01.012.
55Sakata H, Watanabe A, Iwata S, Sato Y, Suzuki K, Miyashita N, Hori S, Yamaguchi Y, Odajima M, Katakuse Y, Hasegawa T, Maki N, Wada K: Surveillance on susceptibility of strains isolated from pediatric infections. J Infect Chemother 25(3-4):163-169,2019. https://doi.org/10.1016/j.jiac.2018.11.004.
56Miyashita N, Horita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Ogasawara K, Kiyota H, Watanabe A: Validation of a diagnostic score model for the prediction of Legionella pneumophila pneumonia. J Infect Chemother 25(6): 407-412,2019(June). https://doi.org/10.1016/j.jiac.2019.03.009.
57Murakami Y, Kanazu S, Petigara T, Oba MS, Nishiwaki Y, Watanabe A: Factors associated with PPSV23 vaccine coverage among older adults in Japan－A nationwide community-based survey. BMJ open 2019;9:e030197. Doi:10.1136/bmjopen-2019-030197 ( https://bmjopen.bmj.com/content/9/7/e030197.info)
58Yamaba Y, Ito Y, Suzuki K, Kikuchi T, Ogawa K, Hasegawa N, Fujiuchi S, Kurashima A, Higuchi T, Uchiya K, Watanabe A, Niimi A: Moxifloxacin resistance and genotyping of Mycobacerium avium and mycobacterium intracellualre isolates in Japan. J Infect Chemother 25(129: 995-1000, 2019. ［https://doi.0rg/10.1016/j.jiac.2019,05.028］
59Hirotsu N, Sakaguchi H, Sato C, Ishibashi T, Shishido T, Tsuchiya K, Hayden FG, Uehara T, and Watanabe A: Baloxavir marboxil in Japanese pediatric patients with influenza: safety, pharmacokinetics and clinical and virogic outcomes. Clinical Infectious Diseases, ciz908, ［https://doi.org/10.1093/cid/ciz908］
60
Miyazaki T, Yanagihara K, Kakeya H, Izumikawa K, Mukae H, Shindo Y, Yamamoto Y, Tateda K, Tomono K, Ishida T, Hasegawa Y, Niki Y, Watanabe A, Soma K and Kohno S: Daily practice and prognostic factors for pneumonia caused by methicillin-resistant Staphylococcus aureus inJapan: A multicenter prospective observational cohort study. J Infect Chemother 26(2):242-251,2020 [https://doi.org/10.1016/j.jiac.2019.08.018]
61

Naito T, Suzuki M, Fujibayashi K, Kanazawa A, Takahashi H, Yokokawa H, Watanabe A: The estimated impact of the 5-year national vaccination program on the trend of 23-valent pneumococcal polysaccharide vaccine vaccination rates in the elderly in Japan, 2009-2018. J Infect Chemother 26(4):407-410,2020［https://doi.org/10.1016/j.jiac.2019.12.011]
62
Saeki H, Terui T, Morita A, Sano S, Imafuku S, Asahina A, Komine M, Etou T, Igarashi A, Torii H, Abe M, Nakagawa H, Watanabe A, Yotsuyanagi H, Ohtsuki M: Japanese guidance for use of biologics for psoriasis (the 2019 version). J Dermatol 47(3):201-222,2020(First published, 08 Jan. 2020) [https://doi.org/10.1111/1346-8138.15196]
63
Tanaka Y, Atsumi T, Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Origasa H, Shoji T, Miyasaka N, oike T: Factors Associated with Successful Discontinuation of Certolizumab Pegol in Early Rheumatoid Arthritis. International Journal of Rheumatic Diseases 23:316-324,2020. [https://doi.org/10.1111/1756-185X.13780]
64
Miyashita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Ogasawara K, Kiyota H and Watanabe A: Distribution of Legionella species and serogroups in patients with culture-confirmed Legionella pneumonia. J Infect Chemother 26:411-417,2020.［https://doi.org/10.1016/j.jiac.2019.12.016］
65
Naito T, Suzuki M, Kanazawa A, takahashi H, Fujibayashi K, Yokokawa H, Kuwatsuru R, and Watanabe A: Pneumococcal vaccination reduces in-hospital mortality, length of stay and medical expenditure in hospitalized elderly patients. J Infect Chemother 26(7):715-721, 2020 [https://doi.org/10.1016/j.jiac.2020.03.016]
66
Suzuki K, Kurono Y, Ikeda K, Hotomi M, Yano H, Watanabe A, Matsumoto T, Takahashi Y, Hanaki H: The seventh nationwide surveillance of six otorhinolaryngological infectious diseases and the antimicrobial susceptibility pattern in the isolated pathogens in Japan. J Infect Chemother 26(9):890-899, 2020. [https://doi.org/10.1016/j.jiac.2020.05.020].
67
Ishida T, Seki M, Oishi K, Tateda K, Fujita J, Kadota J, Kawana A, Izumikawa K, Kikuchi T9, Ohmagari N, Yamada M, Maruyama T, Takazono T, Miki M, Miyazaki Y, Yamazaki Y, Kakeya H, Ogawa K, Nagai H & Watanabe A: Clinical manifestations of adult patients requiring influenza-associated hospitalization; a prospective multicenter cohort study in Japan via internet surveillance. J Infect Chemother 27(2):480-485, 2021. [https://doi.org/10.1016/j.jiac.2020.10.021].
68
Imamura I, Miyazaki T, Watanabe A, Tsukada H, Nagai H, Hasegawa Y, Tomono K, Ito I, Kadota J, Kohno S, and Mukae H: A prospective multicenter survey for nursing and healthcare-associated pneumonia in Japan. J Infect Chemother (published online Apr 9, 2022.) https://doi.org/10.1016/j.jiac.2022.03.030
69
69． Ishida T, Seki M, Oishi K, Tateda K, Fujita J, Kadota J, Kawana A, Izumikawa K, Kikuchi T, Ohmagari N, Yamada M, Maruyama T, Takazono T, Miki M, Miyazaki Y, Yamazaki Y, Kakeya H, Ogawa K, Nagai H & Watanabe A: Clinical manifestations of hospitalized influenza patients without risk factors: A prospective multicenter cohort study in Japan via internet surveillance. J Infect Chemother 28(7):853-858, 2022. https://doi.org/10.1016/j.jiac.2022.02.001
70
70． Imamura I, Miyazaki T, Watanabe A, Tsukada H, Nagai H, Hasegawa Y, Tomono K, Ito I, Teramoto S, Ishida T, Kadota J, Kohno S, and Mukae H: A prospective multicenter survey for nursing and healthcare-associated pneumonia in Japan. J Infect Chemother 28(8):1125-1130, 2022. (Published online Apr 9, 2022.) https://doi.org/10.1016/j.jiac.2022.03.030
71

Naito T, Suzuki M, Fujibayashi K, Kanazawa A, Takahashi H, Yokokawa H, Watanabe A: The estimated impact of the 5-year national vaccination program on the trend of 23-valent pneumococcal polysaccharide vaccine vaccination rates in the elderly in Japan, 2009-2018. J Infect Chemother 26(4):407-410,2020［https://doi.org/10.1016/j.jiac.2019.12.011]
72
Miyashita N, Higa F, Aoki Y, Kikuchi T, Seki M, Tateda K, Maki N, Uchino K, Kiyota H and Watanabe A: Usefulness of the Legionella Score for differentiation from COVID-19 pneumonia to legionella pneumonia. J Infect Chemother 28(10):1353-1357, 2022. (Available online 8 July 2022 https://doi.org/10.1016/j.jiac.2022.06.012
73
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Sano S, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M, and Committee for reviewing the safety of molecuraly targeted drugs for psoriasis, Japanese Dermatological Association: English version of Japanese guidance for use of biologics for psoriasis (the 2022 version). J Dermatol 2022;65:e41-e68. DOI: 10.1111/1346-8138.16691
74
Saeki H, Mabuchi T, Asahina A, Abe M, Igarashi A, Imafuku S, Okubo Y, Komine M, Takahashi K, Torii H, Morita A, Yotsuyanagi H, Watanabe A, Ohtsuki M: English version of Japanese guidance for the use of oral Janus kinase (JAK) inhibitors (JAK1 and TYK2 inhibitors) in the treatments of psoriasis. J Dermatol 2023;50:e138-e150. DOI: 10.1111/1346-8138.16797
75
Kurono Y, Kudo F, Watanabe A, Yamatake T, Shimada S, Suzuki K: Efficacy, safety, and tissue penetrating of Solithromycin in Japanese patients with otorhinolaryngological infections. Auris Nasus Larynx(日本耳鼻咽喉科頭頚部外科学会誌), Online first, Dec.7, 2023. https://doi.org/10.1016/j.anl.2023.11.008
76
76． Kameda H, Nishida K, Nanki T, Watanabe A, Oshima Y, and Momohara S: Safety and effectiveness of certolizumab pegol in Japanese patients with rheumatoid arthritis: Up to 3-year results from a postmarketing surveillance study. Modern Rheumatology 00, 2024, 1-12, DOI: https://doi.org/10.1093/mr/roae019
77
77． Watanabe A, Sumitani T, Kakurai Y and Adachi Y: Efficacy and safe